May 26: Memorial Day in Alexandria Bay
Alexandria Bay Chamber of Commerce will have the Memorial Day Parade & Fireworks on Monday, May 26.
The parade will start at noon with the lineup beginning at 11 a.m. Fireworks will be set off at dusk from Casino Island.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
CoreWeave (CRWV) Is on Wall Street's Radar—But One Analyst Says It's a Trap
CoreWeave, Inc. (NASDAQ:) is one of the 10 AI Stocks on Wall Street's Radar. On June 10, DA Davidson analyst Gil Luria reiterated an 'Underperform' rating on CoreWeave, Inc. (NASDAQ:CRWV) with a $36.00 price target. The firm stated that CoreWeave had disclosed a pro forma contract financing structure example to analysts a day before, which indicated that shareholders will get some returns during the duration of the contracts being signed. However, it believes that the disclosure, even if accepted at face value, 'very clearly illustrates the exact opposite point.' Luria highlighted how there is no upfront equity and no returns to current equity holders during the contract. While the company assumes a 15% equity, the analyst also stated that CoreWeave does not have equity capital to invest and is instead relying on other forms of non-project debt. Such a step would require an additional $590 million, which would result in 'literally wiping out any cash they are claiming to generate for shareholders.' The firm also believes that the illustrative interest rate indicates that all of the company's previous deals are likely unprofitable. Moreover, while AI enthusiasm may likely fuel expansion, it would require the company to raise more than $10 billion in equity capital at the current share price so that it can justify the next two years of projects. This seems as the only significant upside risk to DA's analysis. While we acknowledge the potential of CRWV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
2 hours ago
- Yahoo
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
Viking Therapeutics, Inc. (VKTX) closed at $28.59 in the latest trading session, marking a -1.26% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.38%. On the other hand, the Dow registered a gain of 0.24%, and the technology-centric Nasdaq increased by 0.24%. Prior to today's trading, shares of the company had gained 8.96% outpaced the Medical sector's gain of 4.64% and the S&P 500's gain of 6.6%. The investment community will be paying close attention to the earnings performance of Viking Therapeutics, Inc. in its upcoming release. The company is expected to report EPS of -$0.44, down 120% from the prior-year quarter. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$1.86 per share and revenue of $25 million, indicating changes of -84.16% and 0%, respectively, compared to the previous year. Investors should also note any recent changes to analyst estimates for Viking Therapeutics, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Right now, Viking Therapeutics, Inc. possesses a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 74, which puts it in the top 31% of all 250+ industries. The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Viking Therapeutics, Inc. (VKTX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
IonQ, Inc. (IONQ) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest close session, IonQ, Inc. (IONQ) was down 2.49% at $38.71. This change lagged the S&P 500's 0.38% gain on the day. At the same time, the Dow added 0.24%, and the tech-heavy Nasdaq gained 0.24%. Prior to today's trading, shares of the company had gained 18.83% outpaced the Computer and Technology sector's gain of 11.61% and the S&P 500's gain of 6.6%. The investment community will be paying close attention to the earnings performance of IonQ, Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.13, reflecting a 27.78% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $17.02 million, up 49.56% from the prior-year quarter. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.47 per share and a revenue of $85 million, representing changes of +69.87% and +97.34%, respectively, from the prior year. Investors should also note any recent changes to analyst estimates for IonQ, Inc. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. At present, IonQ, Inc. boasts a Zacks Rank of #2 (Buy). The Computer - Integrated Systems industry is part of the Computer and Technology sector. This industry, currently bearing a Zacks Industry Rank of 54, finds itself in the top 22% echelons of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IonQ, Inc. (IONQ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
